Business Context and Reporting Period
This Form 8-K Current Report was filed by Novavax, Inc. on October 12, 2008. The report discloses the execution of a new employment agreement with a senior officer, effective October 2, 2008.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation terms.
- Base Salary: $236,127 annually for James Robinson (Vice President, Technical and Quality Operations).
- Target Bonus: 40% of base salary, contingent on performance goals.
- Severance: 12 months of salary payable as a lump sum if terminated without cause or for good reason.
Material Changes
The primary material change is the formalization of the employment terms for James Robinson. The agreement includes confidentiality and non-competition provisions, restricting the executive from competing with the company for 12 months post-termination.
Guidance, Outlook, and Risks
The filing contains no financial guidance, market outlook, or discussion of general business risks. The only specific contingency noted is the severance obligation triggered by termination without cause or for good reason.
Investor Verification Checklist
- Verify the total potential cash outlay for the Robinson Agreement, including the maximum bonus and severance scenarios.
- Confirm the impact of the 12-month non-compete clause on the company's ability to hire from competitors in the technical and quality operations sector.
- Review the specific performance goals required to achieve the 40% target bonus, as these are determined by the President, CEO, and Board.
- Check subsequent filings for any amendments to the agreement or changes in Mr. Robinson's status.